905587-17-9

Usage

Uses

Used in Pharmaceutical Industry:
(S)-N-(1-(5-fluoropyridin-2-yl)ethyl)acetamide is used as a potent inhibitor of histone deacetylases (HDACs) for its potential in cancer treatment and neurodegenerative diseases. Its ability to modulate gene expression and regulate cellular processes makes it a valuable candidate for further research in the field of drug development.
Used in Cancer Treatment:
(S)-N-(1-(5-fluoropyridin-2-yl)ethyl)acetamide is used as an anti-tumor agent for its potential in treating various types of cancer. It has shown promising results in preclinical studies, exhibiting anti-tumor effects.
Used in Neurodegenerative Disease Treatment:
(S)-N-(1-(5-fluoropyridin-2-yl)ethyl)acetamide is used as a neuroprotective agent for its potential in treating neurodegenerative diseases. It has demonstrated neuroprotective effects in preclinical studies.

Upstream product

• 327056-62-2 5-fluoropicolinonitrile 
• 905587-18-0 N-(1-(5-fluoropyridin-2-yl)vinyl)acetamide 
• 41404-58-4 2-bromo-5-fluoropyridine 

Downstream Products

• 905587-16-8 (S)-tert-butyl-1-(5-fluoropyridin-2-yl)ethylcarbamate 
• 905587-15-7 (S)-1-(5-fluoropyridin-2-yl)-ethanamine 
• 915720-21-7 AZ23 
• 915720-57-9 1-(5-fluoropyridin-2-yl)ethan-1-amine 

Relevant academic research and scientific papers

Structural Investigations on Enantiopure P–OP Ligands: A High-Performing P–OP Ligand for Rhodium-Catalysed Hydrogenations

A second generation of phosphine–phosphite (P–OP) ligands, incorporating a more sterically bulky phosphite group than previous P–OP ligand designs, gave very efficient catalysts for the Rh-catalysed asymmetric hydrogenation of a diverse array of substrate

SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS

The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.

MaxPHOS ligand: PH/NH tautomerism and rhodium-catalyzed asymmetric hydrogenations

MaxPHOS is an active and robust P-stereogenic ligand for asymmetric catalysis. The presence of an -NH- bridge between the two phosphine moieties allows the NH/PH tautomerism to take place. The neutral ligand, in which the NH form predominates, is an air-sensitive compound. However, protonation of MaxPHOS leads to the stable PH form of the ligand, in which the overall positive charge is distributed on both P centers. This protonation turns the MaxPHOS×HBF4 salt 3 into an air-stable compound both in the solid state and in solution. The salt 3 is also a convenient precursor for the preparation of rhodium(I) complexes by direct ligand exchange with the complex [Rh(acac)(cod)]. Finally, the corresponding rhodium(I)-MaxPHOS complex was tested in the asymmetric hydrogenation of a wide range of substrates. The complex proved to be a highly selective and robust system in these reactions.

Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases

New pyridin-2(1h)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES

Compoundshaving the chemical structure of formula (I) are disclosed; as well as process for theirpreparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

Heteroaryl imidazolone derivatives as jak inhibitors

New heteroaryl imidazolone derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS

New heteroaryl imidazolone derivatives having the chemical structure of formula (I) disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

2-(IMIDAZ0LYLAMIN0)-PYRIDINE DERIVATIVES AND THEIR USE AS JAK KINASE INHIBITORS

The present inv ention relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein Ring A is 5- or 6-membered heteroaryl, wherein said 5- or 6-membered heteroaryl is optionally substituted on carbon with one or more R6

CHEMICAL COMPOUNDS 000-1

The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.

Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors

The design, synthesis and biological evaluation of a series of pyrazol-3-ylamino pyrazines as potent and selective JAK2 kinase inhibitors is reported, along with the pharmacokinetic and pharmacodynamic properties of lead compounds.